Work

Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.

Year: 2026

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps2681

Authors: Stephane Champiat, Luke Kuttschreuter, Neal Shiv Chawla, Louise Carter, Steven Chuan-Hao Kao, Victoria K. Woodcock, Sarah Benafif, T.R. Jeffry Evans, Timothy Guy Humphries, Harriet S. Walter, Andy Karabajakian, Alexandre Grimaldi, Caroline Hoffmann, Andrew Pierce, Kamlesh Kumar Sankhala

Institutions: The University of Texas MD Anderson Cancer Center, Sarcoma Oncology Center, The Christie NHS Foundation Trust, Chris O’Brien Lifehouse, Churchill Hospital, University College Hospital, University College London, Beatson West of Scotland Cancer Centre, University of Glasgow, Linear Clinical Research, University Hospitals of Leicester NHS Trust

Language: English

Topic: Inflammatory mediators and NSAID effects

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162682574

FWCI:

Cites:

Cited by:

Related to: